|
Classical Hodgkin's Lymphoma
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
To conclude, the detection of the XPO1 E571K mutation in biopsy and plasma cell-free DNA by digital PCR may be used as a novel biomarker in classical Hodgkin lymphoma for both diagnosis and minimal residual disease, and pinpoints a crucial role of XPO1 in classical Hodgkin lymphoma pathogenesis.
|
27479820 |
2016 |
|
Adult Classical Hodgkin Lymphoma
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
To conclude, the detection of the XPO1 E571K mutation in biopsy and plasma cell-free DNA by digital PCR may be used as a novel biomarker in classical Hodgkin lymphoma for both diagnosis and minimal residual disease, and pinpoints a crucial role of XPO1 in classical Hodgkin lymphoma pathogenesis.
|
27479820 |
2016 |
|
Adult Classical Hodgkin Lymphoma
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Recent reports have shown molecular alterations in the gene encoding XPO1 and showed a mutation hotspot (E571K) in the following two hematological malignancies with similar phenotypes and natural histories: primary mediastinal diffuse large B cell lymphoma and classical Hodgkin's lymphoma.
|
28196522 |
2017 |
|
Autistic Disorder
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
In XPO1, rs6735330 was associated with autism in all four cohorts (P<0.05), being significant in ASD-CARC cohorts (P-value following false discovery rate correction for multiple testing (P(FDR))=1.29 × 10(-5)), the AGRE cohort (P(FDR)=0.0011) and the combined families (P(FDR)=2.34 × 10(-9)).
|
21750575 |
2011 |
|
Hodgkin Disease
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
XPO1 mutations were present in 28/117 (24%) PMBL cases and in 5/19 (26%) HL cases but absent/rare in MGZL (0/20) or DLBCL (3/197).
|
27312795 |
2016 |
|
Adult Hodgkin Lymphoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
XPO1 mutations were present in 28/117 (24%) PMBL cases and in 5/19 (26%) HL cases but absent/rare in MGZL (0/20) or DLBCL (3/197).
|
27312795 |
2016 |
|
Childhood Hodgkin Lymphoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
XPO1 mutations were present in 28/117 (24%) PMBL cases and in 5/19 (26%) HL cases but absent/rare in MGZL (0/20) or DLBCL (3/197).
|
27312795 |
2016 |
|
Neoplasm, Residual
|
0.010 |
GeneticVariation
|
phenotype |
BEFREE |
Therefore, it was proposed that the XPO1 E571K variant may serve as a minimal residual disease tool in this setting.
|
28196522 |
2017 |
|
Drug-Induced Liver Disease
|
0.010 |
GeneticVariation
|
phenotype |
BEFREE |
Based on this 1:2 matched case-control study, the AA genotype of rs4430924 in XPO1 may be associated with higher risk of anti-TB drug-induced hepatotoxicity in Chinese anti-TB treatment patients.
|
30817003 |
2019 |
|
Adult Diffuse Large B-Cell Lymphoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Recent reports have shown molecular alterations in the gene encoding XPO1 and showed a mutation hotspot (E571K) in the following two hematological malignancies with similar phenotypes and natural histories: primary mediastinal diffuse large B cell lymphoma and classical Hodgkin's lymphoma.
|
28196522 |
2017 |
|
Mediastinal B-Cell Lymphoma, Unclassifiable, with Features Intermediate between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
XPO1 mutations were present in 28/117 (24%) PMBL cases and in 5/19 (26%) HL cases but absent/rare in MGZL (0/20) or DLBCL (3/197).
|
27312795 |
2016 |
|
Monoclonal B-Cell Lymphocytosis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Excepting NOTCH1, TP53 and XPO1, which showed a lower incidence in MBL, genes were mutated with a similar prevalence to CLL, indicating the early origin of most driver mutations in the MBL/CLL continuum.
|
27469216 |
2017 |
|
Chronic Lymphocytic Leukemia
|
0.440 |
Biomarker
|
disease |
BEFREE |
Together, these findings demonstrate that XPO1 is a valid target in CLL with minimal effects on normal cells and provide a basis for the development of SINEs in CLL and related hematologic malignancies.
|
23034282 |
2012 |
|
Chronic Lymphocytic Leukemia
|
0.440 |
Biomarker
|
disease |
BEFREE |
The survival of chronic lymphocytic leukaemia (CLL) cells, among other cancer cells, is assisted by the deregulation of nuclear to cytoplasmic shuttling, at least in part through deregulation of the transport receptor XPO1 and the constitutive activation of PI3K-mediated signaling pathways.
|
31710039 |
2019 |
|
Malignant neoplasm of prostate
|
0.340 |
Biomarker
|
disease |
BEFREE |
Therefore, XPO1 inhibition could be a novel promising agent used in combination with conventional chemotherapeutics and AR-targeted therapy for the better treatment of PCa, especially CRPC.
|
30450161 |
2018 |
|
Malignant neoplasm of prostate
|
0.340 |
Biomarker
|
disease |
CTD_human |
The long tail of oncogenic drivers in prostate cancer.
|
29610475 |
2018 |
|
Malignant neoplasm of prostate
|
0.340 |
Biomarker
|
disease |
BEFREE |
PXD101 potentiates hormonal therapy and prevents the onset of castration-resistant phenotype modulating androgen receptor, HSP90, and CRM1 in preclinical models of prostate cancer.
|
23507703 |
2013 |
|
Atrial Fibrillation
|
0.300 |
Biomarker
|
disease |
CTD_human |
Multi-ethnic genome-wide association study for atrial fibrillation.
|
29892015 |
2018 |
|
Prostatic Neoplasms
|
0.300 |
Biomarker
|
group |
CTD_human |
The long tail of oncogenic drivers in prostate cancer.
|
29610475 |
2018 |
|
Paroxysmal atrial fibrillation
|
0.300 |
Biomarker
|
disease |
CTD_human |
Multi-ethnic genome-wide association study for atrial fibrillation.
|
29892015 |
2018 |
|
Persistent atrial fibrillation
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Multi-ethnic genome-wide association study for atrial fibrillation.
|
29892015 |
2018 |
|
familial atrial fibrillation
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Multi-ethnic genome-wide association study for atrial fibrillation.
|
29892015 |
2018 |
|
Mammary Neoplasms
|
0.120 |
Biomarker
|
group |
BEFREE |
Remodeling metabolic pathways to regenerate new vulnerabilities in endocrine resistant breast tumors is novel, and given the need for better strategies to improve therapy response in relapsed ERα (+) tumors, our findings show great promise for uncovering the role that ERα-XPO1 crosstalk plays in reducing cancer recurrences.
|
30987380 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Chromosome region maintenance 1 (CRM1) exports nuclear export signal (NES) containing cargos from nucleus to cytoplasm and plays critical roles in cancer and viral infections.
|
31495993 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our findings provide strong rationale for inhibiting XPO1 as an innovative strategy for the combined anti-retroviral and anti-neoplastic treatment of HIV and PEL and offer perspectives for the treatment of other AIDS-associated cancers and potentially other virus-related malignancies.
|
26501108 |
2015 |